FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105133921> ?p ?o ?g. }

• W2105133921 abstract "Triple-negative breast cancers need to be refined in order to identify therapeutic subgroups of patients. We conducted an unsupervised analysis of microarray gene-expression profiles of 107 triple-negative breast cancer patients and undertook robust functional annotation of the molecular entities found by means of numerous approaches including immunohistochemistry and gene-expression signatures. A triple-negative external cohort (n = 87) was used for validation. Fuzzy clustering separated triple-negative tumours into three clusters: C1 (22.4%), C2 (44.9%) and C3 (32.7%). C1 patients were older (mean = 64.6 years) than C2 (mean = 56.8 years; P = 0.03) and C3 patients (mean = 51.9 years; P = 0.0004). Histological grade and Nottingham prognostic index were higher in C2 and C3 than in C1 (P < 0.0001 for both comparisons). Significant event-free survival (P = 0.03) was found according to cluster membership: patients belonging to C3 had a better outcome than patients in C1 (P = 0.01) and C2 (P = 0.02). Event-free survival analysis results were confirmed when our cohort was pooled with the external cohort (n = 194; P = 0.01). Functional annotation showed that 22% of triple-negative patients were not basal-like (C1). C1 was enriched in luminal subtypes and positive androgen receptor (luminal androgen receptor). C2 could be considered as an almost pure basal-like cluster. C3, enriched in basal-like subtypes but to a lesser extent, included 26% of claudin-low subtypes. Dissection of immune response showed that high immune response and low M2-like macrophages were a hallmark of C3, and that these patients had a better event-free survival than C2 patients, characterized by low immune response and high M2-like macrophages: P = 0.02 for our cohort, and P = 0.03 for pooled cohorts. We identified three subtypes of triple-negative patients: luminal androgen receptor (22%), basal-like with low immune response and high M2-like macrophages (45%), and basal-enriched with high immune response and low M2-like macrophages (33%). We noted out that macrophages and other immune effectors offer a variety of therapeutic targets in breast cancer, and particularly in triple-negative basal-like tumours. Furthermore, we showed that CK5 antibody was better suited than CK5/6 antibody to subtype triple-negative patients." @default.
• W2105133921 created "2016-06-24" @default.
• W2105133921 creator A5001022411 @default.
• W2105133921 creator A5003056868 @default.
• W2105133921 creator A5018363275 @default.
• W2105133921 creator A5036430313 @default.
• W2105133921 creator A5051763478 @default.
• W2105133921 creator A5058936500 @default.
• W2105133921 creator A5071553983 @default.
• W2105133921 creator A5077349622 @default.
• W2105133921 creator A5083974898 @default.
• W2105133921 creator A5084605464 @default.
• W2105133921 creator A5086200109 @default.
• W2105133921 date "2015-03-20" @default.
• W2105133921 modified "2023-10-18" @default.
• W2105133921 title "Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response" @default.
• W2105133921 cites W1546709038 @default.
• W2105133921 cites W1970490725 @default.
• W2105133921 cites W1983134755 @default.
• W2105133921 cites W1989938935 @default.
• W2105133921 cites W1990148464 @default.
• W2105133921 cites W1991527725 @default.
• W2105133921 cites W1991808539 @default.
• W2105133921 cites W1999873680 @default.
• W2105133921 cites W2000895026 @default.
• W2105133921 cites W2007997332 @default.
• W2105133921 cites W2022816557 @default.
• W2105133921 cites W2028426093 @default.
• W2105133921 cites W2033278321 @default.
• W2105133921 cites W2038963685 @default.
• W2105133921 cites W2041009568 @default.
• W2105133921 cites W2044702943 @default.
• W2105133921 cites W2047656598 @default.
• W2105133921 cites W2052481226 @default.
• W2105133921 cites W2053122486 @default.
• W2105133921 cites W2058648826 @default.
• W2105133921 cites W2064084120 @default.
• W2105133921 cites W2065210647 @default.
• W2105133921 cites W2081810806 @default.
• W2105133921 cites W2096027508 @default.
• W2105133921 cites W2097255042 @default.
• W2105133921 cites W2098683355 @default.
• W2105133921 cites W2099335989 @default.
• W2105133921 cites W2101195992 @default.
• W2105133921 cites W2106292881 @default.
• W2105133921 cites W2112434826 @default.
• W2105133921 cites W2114505219 @default.
• W2105133921 cites W2117246760 @default.
• W2105133921 cites W2120431466 @default.
• W2105133921 cites W2124649657 @default.
• W2105133921 cites W2129643153 @default.
• W2105133921 cites W2130598050 @default.
• W2105133921 cites W2130599708 @default.
• W2105133921 cites W2131994307 @default.
• W2105133921 cites W2132619562 @default.
• W2105133921 cites W2133465414 @default.
• W2105133921 cites W2134539328 @default.
• W2105133921 cites W2135548733 @default.
• W2105133921 cites W2145552137 @default.
• W2105133921 cites W2153206149 @default.
• W2105133921 cites W2154453972 @default.
• W2105133921 cites W2157840751 @default.
• W2105133921 cites W2158217645 @default.
• W2105133921 cites W2158795833 @default.
• W2105133921 cites W2159175636 @default.
• W2105133921 cites W2159274850 @default.
• W2105133921 cites W2159560463 @default.
• W2105133921 cites W2165699971 @default.
• W2105133921 cites W2166311434 @default.
• W2105133921 cites W2167685929 @default.
• W2105133921 cites W2259802687 @default.
• W2105133921 cites W2560367415 @default.
• W2105133921 cites W4245806510 @default.
• W2105133921 doi "https://doi.org/10.1186/s13058-015-0550-y" @default.
• W2105133921 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4389408" @default.
• W2105133921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25887482" @default.
• W2105133921 hasPublicationYear "2015" @default.
• W2105133921 type Work @default.
• W2105133921 sameAs 2105133921 @default.
• W2105133921 citedByCount "222" @default.
• W2105133921 countsByYear W21051339212015 @default.
• W2105133921 countsByYear W21051339212016 @default.
• W2105133921 countsByYear W21051339212017 @default.
• W2105133921 countsByYear W21051339212018 @default.
• W2105133921 countsByYear W21051339212019 @default.
• W2105133921 countsByYear W21051339212020 @default.
• W2105133921 countsByYear W21051339212021 @default.
• W2105133921 countsByYear W21051339212022 @default.
• W2105133921 countsByYear W21051339212023 @default.
• W2105133921 crossrefType "journal-article" @default.
• W2105133921 hasAuthorship W2105133921A5001022411 @default.
• W2105133921 hasAuthorship W2105133921A5003056868 @default.
• W2105133921 hasAuthorship W2105133921A5018363275 @default.
• W2105133921 hasAuthorship W2105133921A5036430313 @default.
• W2105133921 hasAuthorship W2105133921A5051763478 @default.
• W2105133921 hasAuthorship W2105133921A5058936500 @default.
• W2105133921 hasAuthorship W2105133921A5071553983 @default.
• W2105133921 hasAuthorship W2105133921A5077349622 @default.
• W2105133921 hasAuthorship W2105133921A5083974898 @default.
• W2105133921 hasAuthorship W2105133921A5084605464 @default.

• next